Gene · 8438
Papers1,865
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,865
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Impact of DNA damage repair alterations on prostate cancer progression and metastasis. | Front Oncol | 2023 | 37434977 | PubTator, text mining | PubMed |
| Analysis of the CHD7 gene mutations in patients of congenital heart disease with extracardiac malformations. | Transl Pediatr | 2023 | 37427070 | PubTator, text mining | PubMed |
| Recent Research Advances in Double-Strand Break and Mismatch Repair Defects in Prostate Cancer and Potential Clinical Applications. | Cells | 2023 | 37408208 | PubTator, text mining | PubMed |
| Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs. | Res Rep Urol | 2023 | 37396015 | PubTator, text mining | PubMed |
| Repair of topoisomerase 1-induced DNA damage by tyrosyl-DNA phosphodiesterase 2 (TDP2) is dependent on its magnesium binding. | J Biol Chem | 2023 | 37392847 | PubTator, text mining | PubMed |
| A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle. | J Transl Med | 2023 | 37386467 | PubTator, text mining | PubMed |
| Comparative Survival Benefits of Surgery and Adjuvant Chemotherapy in Neuroendocrine Carcinoma of the Gallbladder: A Population-Based Study with Insight into Future Personalized Therapeutic Approach. | J Pers Med | 2023 | 37373998 | PubTator, text mining | PubMed |
| Impact of Manganese and Chromate on Specific DNA Double-Strand Break Repair Pathways. | Int J Mol Sci | 2023 | 37373538 | PubTator, text mining | PubMed |
| Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian Cancer in a Gynecologic Oncology Practice. | Cancers (Basel) | 2023 | 37370804 | PubTator, text mining | PubMed |
| Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells. | Mol Cancer Res | 2023 | 37358557 | PubTator, text mining | PubMed |
| A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. | Oncologist | 2023 | 37354528 | PubTator, text mining | PubMed |
| Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors. | PeerJ | 2023 | 37334114 | PubTator, text mining | PubMed |
| Molecular mechanisms of Holliday junction branch migration catalyzed by an asymmetric RuvB hexamer. | Nat Commun | 2023 | 37322069 | PubTator, text mining | PubMed |
| The Curcumin Analog PAC Is a Potential Solution for the Treatment of Triple-Negative Breast Cancer by Modulating the Gene Expression of DNA Repair Pathways. | Int J Mol Sci | 2023 | 37298600 | PubTator, text mining | PubMed |
| The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study. | Cancers (Basel) | 2023 | 37296992 | PubTator, text mining | PubMed |
| Mec1-independent activation of the Rad53 checkpoint kinase revealed by quantitative analysis of protein localization dynamics. | Elife | 2023 | 37278514 | PubTator, text mining | PubMed |
| Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. | Int J Mol Sci | 2023 | 37240284 | PubTator, text mining | PubMed |
| DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC. | Int J Mol Sci | 2023 | 37240218 | PubTator, text mining | PubMed |
| Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks. | Int J Mol Sci | 2023 | 37240063 | PubTator, text mining | PubMed |
| Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort. | Int J Mol Sci | 2023 | 37239898 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8438/papers?page=10